Sitagliptin	Sulphonylurea	Risk of symptomatic hypoglycaemia	1381	1577	The risk of symptomatic hypoglycaemia was significantly decreased with sitagliptin relative to sulphonylurea treatment (Mantel–Haenszel relative risk ratio [95% CI] = 0.51 [0.34, 0.75]; p < 0.001)
Sitagliptin	Sulphonylurea	Risk of symptomatic hypoglycaemia	1381	1578	The risk of symptomatic hypoglycaemia was significantly decreased with sitagliptin relative to sulphonylurea treatment (Mantel–Haenszel relative risk ratio [95% CI] = 0.51 [0.34, 0.75]; p < 0.001).
Sitagliptin	Sulphonylurea	Risk of asymptomatic hypoglycaemia	22215	22428	The risk of symptomatic or asymptomatic hypoglycaemia was significantly decreased with sitagliptin relative to sulphonylurea treatment (Mantel–Haenszel relative risk ratio [95% CI] = 0.50 [0.36, 0.69]; p < 0.001).
Sitagliptin	Sulphonylurea	Risk of asymptomatic hypoglycaemia	22215	22427	The risk of symptomatic or asymptomatic hypoglycaemia was significantly decreased with sitagliptin relative to sulphonylurea treatment (Mantel–Haenszel relative risk ratio [95% CI] = 0.50 [0.36, 0.69]; p < 0.001)
